Safety profile
toxicities
ADVERSE EVENTS, ADVERSE EVENT
A median 6 cycles of chemotherapy were given for both groups. Study treatment was discontinued due to toxicities in 10% and 3% of patients in the S + XP and XP arms, respectively. Doses of capecitabine and cisplatin were reduced due to the toxicities in 63% and 57%, respectively, in the S + XP arm, and 68% and 68%, respectively, in the XP arm. The dose of sorafenib was reduced in 20% of patients in the S + XP arm. Relative dose intensities of capecitabine and cisplatin were 83% and 85%, respectively, in the S + XP arm and 85% and 82%, respectively, in the XP arm. The dose intensity of sorafenib in the S + XP arm was 90%.The adverse events are summarized in Table Adverse events.All gradesNo. (%)Grade 3/4No. (%)All gradesNo. (%)Grade 3/4No. (%)Abbreviations: AE, adverse events; S, sorafenib; XP, capecitabine and cisplatin.Adverse events were not evaluated in two patients in XP arm due to early loss to follow‐up.